Cargando…
In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies
Background: We assumed that the pharmacokinetics of lovastatin could be changed by the induction effect of berberine. Methods: An UPLC-MS/MS method was developed and validated for the pharmacokinetics tudy of lovastatin to investigate the in vivo drug-drug interactions between lovastatin and berberi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272956/ https://www.ncbi.nlm.nih.gov/pubmed/27070564 http://dx.doi.org/10.3390/molecules21040464 |
_version_ | 1783377273185894400 |
---|---|
author | Cui, Hanming Wang, Jialong Zhang, Qiuyan Dang, Mengmeng Liu, Hui Dong, Yu Zhang, Lu Yang, Fang Wu, Jianhua Tong, Xiaolin |
author_facet | Cui, Hanming Wang, Jialong Zhang, Qiuyan Dang, Mengmeng Liu, Hui Dong, Yu Zhang, Lu Yang, Fang Wu, Jianhua Tong, Xiaolin |
author_sort | Cui, Hanming |
collection | PubMed |
description | Background: We assumed that the pharmacokinetics of lovastatin could be changed by the induction effect of berberine. Methods: An UPLC-MS/MS method was developed and validated for the pharmacokinetics tudy of lovastatin to investigate the in vivo drug-drug interactions between lovastatin and berberine. SD male rats were random divided into lovastatin group and berberine induced prior to lovastatin group for the in vivo pharmacokinetic studies. Meanwhile HepG2 cells were induced by berberine for three days to study the metabolism of lovastatin. Results: The AUC (p < 0.01) and C(max) (p < 0.01) could be significantly decreased in the berberine-induced group in vivo, and the metabolic activity of HepG2 cell ccould be increased by berberine induction in vitro. The metabolism parameters of lovastatin such as CL, V(max) and K(m) were increased after the induction of berberine. From the pharmacokinetic study of lovastatin induced with berberine, we obtained pharmacokinetic parameters which are compliance with the metabolic parameters of lovastatin in HepG2 cells with berberine induction in vitro. Conclusions: From the in vivo pharmacokinetics study and the HepG2 cell metabolism study in vitro, berberine could be an inducer for the metabolism of lovastatin according to our previous research on berberine induction effects on HepG2 cells, which may be relevant to the fact that berberine possesses induction effects through the CYP 450 3A4 enzyme. |
format | Online Article Text |
id | pubmed-6272956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62729562018-12-28 In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies Cui, Hanming Wang, Jialong Zhang, Qiuyan Dang, Mengmeng Liu, Hui Dong, Yu Zhang, Lu Yang, Fang Wu, Jianhua Tong, Xiaolin Molecules Article Background: We assumed that the pharmacokinetics of lovastatin could be changed by the induction effect of berberine. Methods: An UPLC-MS/MS method was developed and validated for the pharmacokinetics tudy of lovastatin to investigate the in vivo drug-drug interactions between lovastatin and berberine. SD male rats were random divided into lovastatin group and berberine induced prior to lovastatin group for the in vivo pharmacokinetic studies. Meanwhile HepG2 cells were induced by berberine for three days to study the metabolism of lovastatin. Results: The AUC (p < 0.01) and C(max) (p < 0.01) could be significantly decreased in the berberine-induced group in vivo, and the metabolic activity of HepG2 cell ccould be increased by berberine induction in vitro. The metabolism parameters of lovastatin such as CL, V(max) and K(m) were increased after the induction of berberine. From the pharmacokinetic study of lovastatin induced with berberine, we obtained pharmacokinetic parameters which are compliance with the metabolic parameters of lovastatin in HepG2 cells with berberine induction in vitro. Conclusions: From the in vivo pharmacokinetics study and the HepG2 cell metabolism study in vitro, berberine could be an inducer for the metabolism of lovastatin according to our previous research on berberine induction effects on HepG2 cells, which may be relevant to the fact that berberine possesses induction effects through the CYP 450 3A4 enzyme. MDPI 2016-04-08 /pmc/articles/PMC6272956/ /pubmed/27070564 http://dx.doi.org/10.3390/molecules21040464 Text en © 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cui, Hanming Wang, Jialong Zhang, Qiuyan Dang, Mengmeng Liu, Hui Dong, Yu Zhang, Lu Yang, Fang Wu, Jianhua Tong, Xiaolin In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies |
title | In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies |
title_full | In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies |
title_fullStr | In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies |
title_full_unstemmed | In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies |
title_short | In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies |
title_sort | in vivo and in vitro study on drug-drug interaction of lovastatin and berberine from pharmacokinetic and hepg2 cell metabolism studies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272956/ https://www.ncbi.nlm.nih.gov/pubmed/27070564 http://dx.doi.org/10.3390/molecules21040464 |
work_keys_str_mv | AT cuihanming invivoandinvitrostudyondrugdruginteractionoflovastatinandberberinefrompharmacokineticandhepg2cellmetabolismstudies AT wangjialong invivoandinvitrostudyondrugdruginteractionoflovastatinandberberinefrompharmacokineticandhepg2cellmetabolismstudies AT zhangqiuyan invivoandinvitrostudyondrugdruginteractionoflovastatinandberberinefrompharmacokineticandhepg2cellmetabolismstudies AT dangmengmeng invivoandinvitrostudyondrugdruginteractionoflovastatinandberberinefrompharmacokineticandhepg2cellmetabolismstudies AT liuhui invivoandinvitrostudyondrugdruginteractionoflovastatinandberberinefrompharmacokineticandhepg2cellmetabolismstudies AT dongyu invivoandinvitrostudyondrugdruginteractionoflovastatinandberberinefrompharmacokineticandhepg2cellmetabolismstudies AT zhanglu invivoandinvitrostudyondrugdruginteractionoflovastatinandberberinefrompharmacokineticandhepg2cellmetabolismstudies AT yangfang invivoandinvitrostudyondrugdruginteractionoflovastatinandberberinefrompharmacokineticandhepg2cellmetabolismstudies AT wujianhua invivoandinvitrostudyondrugdruginteractionoflovastatinandberberinefrompharmacokineticandhepg2cellmetabolismstudies AT tongxiaolin invivoandinvitrostudyondrugdruginteractionoflovastatinandberberinefrompharmacokineticandhepg2cellmetabolismstudies |